← Leaderboards
Christopher Hulme
Iluminos Therapeutics, Llc
$7,256,107
Attributed
$15,887,766
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,887,766 · 5
By mechanism
RC2$7,551,983 · 1
R01$3,770,471 · 1
R44$2,924,902 · 1
P41$1,141,776 · 1
R42$498,634 · 1
Top collaborators
- Travis L Dunckley5 shared
- Travis Dunckley3 shared
- Nathalie Meurice2 shared
- Michael E. Berens1 shared
- Spyro Mousses1 shared
Most similar at Iluminos Therapeutics, Llc
Same institution · by research overlap
- Travis Dunckley$1,711,768
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPharmaceutical ChemistryDesignMedicalStructureSmall MoleculeBaseNerve DegenerationPharmaceutical PreparationsPhosphotransferasesMouse ModelMotorIn VitroNeuropathologyImpaired CognitionIn VivoCognitionChronicCognitiveExhibitsAmyloid Pathology3xtg-Ad MouseBrainCognitive Deficits
Grant awards (13)
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,428,499
R44 · FY2025 · NS
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,496,403
R44 · FY2024 · NS
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease$736,628
R01 · FY2024 · AG · contact PI
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease$744,799
R01 · FY2023 · AG · contact PI
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease$752,581
R01 · FY2022 · AG · contact PI
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$498,634
R42 · FY2022 · NS
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease$757,693
R01 · FY2021 · AG · contact PI
DYRK1A Inhibition as a Novel Treatment Approach for Alzheimer's Disease$778,770
R01 · FY2020 · AG · contact PI
Expeditious, biologically driven Pilot Libraries for File Enhancement$375,406
P41 · FY2012 · GM · contact PI
Expeditious, biologically driven Pilot Libraries for File Enhancement$375,634
P41 · FY2011 · GM · contact PI
The Southwest Comprehensive Center for Drug Discovery and Development$2,700,503
RC2 · FY2010 · MH
Expeditious, biologically driven Pilot Libraries for File Enhancement$390,736
P41 · FY2010 · GM · contact PI
The Southwest Comprehensive Center for Drug Discovery and Development$4,851,480
RC2 · FY2009 · MH